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EDITORIAL REVIEW
Diagnostic significance of hypocomplementemia
Certain immune complex (IC)-mediated diseases frequently
cause hypocomplementemia as assessed by measurement of
serum or plasma C3, C4 or CH5O (third component of the
complement system, fourth component of the complement
system and hemolytic complement activity, respectively).
Thus, the measurement of serum or plasma C3, C4 and CHSO is
used commonly to assess for the presence of an IC-mediated
disease or, in patients with a known IC disorder, to assess for
disease activity [1). However, there are numerous non-immu-
nologic conditions that also can cause hypocomplementemia. It
is important for the clinician to be aware of the non-immuno-
logic conditions that cause hypocomplementemia because some
can induce a systemic disorder that can easily be confused with
an IC-mediated vasculitis. In addition, a non-immunologic
condition that causes hypocomplementemia could develop in a
patient with an IC-mediated disease that is inactive. If the
physician does not recognize that the hypocomplementemia is
the result of the nonimmunologic condition, this could lead to
incorrect treatment of the patient. Although the literature on
complement is voluminous and includes excellent recent re-
views of disorders of complement metabolism [2, 3] and its
importance in the diagnosis of renal disease [4], to our knowl-
edge there is no previous publication that attempts to provide a
comprehensive listing of the causes of hypocomplementemia
and its differential diagnosis. It is the purpose of this work to
provide that listing, with annotations regarding differential
diagnosis, and to discuss several other issues relevant to the
evaluation of the hypocomplementemic patient.
Pathophysiology of hypocompiementemia
A detailed discussion of the complement system is beyond
the scope of this work, which is intended primarily as a clinical
guide to the evaluation of the patient who is found to be
hypocomplementemic by measurement of C3, C4 or CH5O.
However, to provide a general schema for understanding the
pathophysiology of hypocomplementemia, an overview of the
complement system is shown in Table 1 and discussed below.
As shown in Table 1, hypocomplementemia can occur as a
result of activation of the classical or alternative pathways.
Classical pathway activation occurs when Clq binds to an
immune complex (or to certain tumor cells or viruses) causing
the assembly of the Cl complex (Clq + 2Clr + 2Cls), which
cleaves and activates C4 to bind C2 which is then cleaved and
activated. These steps result in the formation of C4b2b which
cleaves C3 into its active form C3b. C3b bound to a surface can
bind C5, permitting a nearby C4b2b to cleave and activate C5 to
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C5b, which then binds C6 and C7. C5b-7 then releases from its
C3b binding site, inserting into a nearby cell membrane. The
C5b-7 complex then assembles the membrane attack complex
(MAC), C5b-8, poly C9. MAC results in injury to that cell by
forming channels and by disrupting the cell membrane.
Classical pathway activation by IC requires first that the
immune system recognize an antigen and mount a specific
antibody response to it. By contrast, alternative pathway acti-
vation can occur in the absence of immune recognition. What is
required for alternative pathway activation is that C3 become
activated, which is constantly occurring at a low rate in plasma
because of hydrolysis of C3 to C3(H20), and bind factor B to
permit factor B cleavage by factor D, to form the C3 convertase
C3bBb. C3bBb in the fluid phase forms metastable C3b which
binds to a surface. Once bound, C3b can bind factor B, permit
cleavage of factor B by factor D, thereby forming on the surface
the C3 convertase C3bBb. This convertase results in the
formation of more C3b which bind to the surface and permit
attachment of CS to the C3b molecule. The CS attached to C3b
is now susceptible to cleavage by C3bBb, thereby activating the
terminal pathway, as described above. Alternative pathway
activation is enhanced when C3b molecules bind to surfaces
that inhibit the inactivation of C3b. Typically such "activator"
surfaces are complex polysaccharides (such as, dialysis mem-
branes) or lipopolysaccharides (such as, bacterial cell walls).
For simplicity's sake, the control mechanisms of the comple-
ment system, except for factor D, are not shown in Table 1.
However, these proteins play an important role in regulating
complement activation. The control mechanisms of the com-
plement system include: Cl inhibitor (a plasma protein that
inhibits Cl by binding to Cir and Cis), C4-binding protein
(C4BP, a plasma protein that promotes the dissociation of C4b
from C2b and provides co-factor activity for the degradation of
C4b by factor I, a plasma protein that inactivates C3b and C4b).
Factor H (a plasma protein that serves as a co-factor which
increases the efficiency of factor I to degrade C3b and C4b),
complement receptor Type 1 (CR1, a membrane protein that is
present on primate erythrocytes, most leukocytes, and glomer-
ular epithelial cells, which acts as a co-factor for factor I
degradation of C3b and C4b), decay accelerating factor (DAF,
a membrane protein present on all cells which accelerates the
decay of both the classical and alternative pathway C3/C5
convertases, properdin (a plasma protein that binds to C3bBb to
stabilize its C3/C5 convertase activity), factor D (a plasma
protein that cleaves factor B to its active form Bb), and S
protein (vitronectin, a plasma protein that binds to CSb-7
released from C3b and prevents the CSb-7 from inserting into
nearby targets.
As can be seen from Table 1, classical pathway activation
results in the consumption of both C3 and C4. By contrast,
activation of the alternative pathway results in consumption of
C3 but not C4. Thus, a reduction in both C3 and C4 levels is
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Table 1. Pathways for complement activation
Classical pathway (CP) Comment
I) Activators: IgG, 1gM Most common activators ofCP
containing IC (left) or AP (right)
Alternative pathway (AP)
I) Activators: IgA containing
IC. Damaged tissue. Gram
negative bacteria.
2) Clq binds to IC causing
assembly of a complex '
(Clq,C1r2,C1s2) which
cleaves C4 and C2 to form an
enzymatically active complex
C4b2b.
3) C4b2b cleaves C3 forming -....
C3a and C3b. C3b binds to --..—-—
a surface or to the IC.
I
——
4) C3b binds CS permitting a
nearby C4b2b to cleave CS
to C5b and C5a. C5b is
temporarily bound to C3b.
Step that initiates activation
of CP (left) or AP (right)
..,C4 is consumed /
.-
— /
C3 is consumed
The anaphylatoxin C3a
is released.
—
—
This step leads to
"amplification" of complement
activation because each
C3bBb begets more C3b's,
which beget more C3bBb's,
etc. The generation of C3b
by the CP can also generate
C3bBb.
The anaphylatoxin C5a is
released
C5b, after binding to C6 and 7, is
released from C3b and inserts
into the nearest cell surface,
causing assembly and activation
of the CSb,6,7,8,9 complex
(Membrane attack complex
(MAC), C5-9 lytic complex).
This complex, which is attached
to the cell membrane, cause
injury to that cell.
2) C3 is hydrolyzed
permitting factor B to bind to
C3. B is cleaved by factor D.
The fluid-phase complex
C3bBb is formed which
cleaves C3 to C3b which then
binds to the activator surface.
Surface bound C3b binds
factor B. D cleaves B forming
C3bBb on the surface.
3) C3bBb cleaves C3 forming
C3a and C3b.
4) More C3bBb is formed
when the nascent C3b binds
to the surface.
5) Some of the surface bound
C3bBb binds near another
C3b forming (C3b)2Bb, which
is a C5 convertase.
6) (C3b)2Bb cleaves C5 to C5a
and C5b. The C5b is
temporarily bound to C3b.
See text for more detail concerning the mechanisms of complement activation and for discussion of the control proteins of the complement
system.
evidence for activation of the classical pathway. By contrast, a
reduction in C3 but normal C4 is evidence for activation of the
alternative pathway. However, there are numerous exceptions
to this "rule," as discussed herein. Low C3, C4, or CH5O levels
can also occur as a result of decreased synthesis of complement
components, or increased consumption of complement compo-
nents, because inadequate function of the inhibitors of comple-
ment activation permits unregulated complement activation.
The role of these mechanisms in causing hypocomplementemia
is also discussed.
Clinical laboratory assessment of the complement system
Initial assessment of complement Status
For the patient being evaluated for the first time the measure-
ment of plasma or serum CH5O, C3 and C4 levels is recom-
mended. The CH5O assay assesses the overall function of the
classical and terminal pathway components Cl to C8 (C9 is not
required for hemolysis of sheep erythrocytes) [1]. The CH5O
assay determines the capacity of the patient's serum to support
complement-mediated lysis of sheep erythrocytes that have
been coated with anti-sheep erythrocyte antibodies capable of
activating the classical pathway. If a complement component is
absent, as in congenital C2 deficiency, the patient's serum C3
and C4 levels will be normal but hemolytic activity, assessed by
the CH5O assay, will be lacking. Thus, the measurement of
CH5O is useful as a screening test for hypocomplementemic
states that would be missed if only C3 and C4 levels are
measured. The CH5O assay is less useful as a monitor of serial
changes in serum complement levels because, for example, C3
and C4 levels may be abnormally low, yet the capacity of the
Terminal pathway
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Fig. 1. Relationship between the upper and lower limits of normal for
serum C3 levels at the 14 Centers involved in the NIH-sponsored Trial
of Plasmapheresis in Severe SLE Nephritis. The Centers are arranged
in ascending order according to the lower limits of normal for serum C3
levels. Note that values for the upper limits of normal for C3 do not
parallel the values for lower limits of normal for C3.
patient's serum to hemolyze the sensitized sheep erythrocytes
may remain within the normal range [1, unpublished observa-
tions]. A CH100 assay (Sigma Diagnostics, St. Louis, Missouri;
Kallestad Diagnostics, Austin, Texas, USA) is an alternative to
a CHS0 assay and is said to be easier to perform.
Serum C3 and C4 levels can be measured functionally, but
usually are measured by an antigenic assay using polyclonal
antibodies against C3 or C4, and radial immunodiffusion or
nephelometry for detection of the antigen-antibody reaction.
Storing blood specimens at room temperature, even for several
days, has little effect on the antigenic assay for C3 and C4. That
is, although degradation of C3 and C4 occurs during storage of
blood at room temperature, the degradation products remain
reactive with the polyclonal antibodies used to detect C3 and
C4. However, for the CH5O assay (a "functional assay") the
blood specimens must be drawn into EDTA (to prevent in vitro
complement activation) or the serum separated from the blood
cells within one hour of obtaining the blood sample, and frozen
at —20°C (short term) or —70°C (long term) until assayed. In
rare SLE patients, allowing the blood sample to clot at room
temperature results in a low CH5O level because of consump-
tion of Cl, C4, and C2. This does not occur when the blood is
allowed to clot at 37°C or is drawn into EDTA [5]. Thus,
allowing blood specimens to clot at room temperature is not
recommended if functional assays are to be performed. The
method of collecting blood from the patient by venipuncture
versus an indwelling venous or arterial catheter appears to be
unimportant because assays for blood complement levels have
the same result by all three methods of blood collection [6].
The normal range for serum C3 varies considerably from
laboratory to laboratory. Figure 1 shows the normal range of C3
levels for the 14 Centers involved in the NIH-sponsored multi-
center trial of plasmapheresis in severe SLE nephritis [7, 8].
Note that the lower limit of normal for serum C3 ranges from 70
to 116 m%, a difference of 66%. Note also that the upper limits
of normal at these Centers do not parallel the values for the
lower limits of normal. This suggests that the differences among
the Centers with respect to the lower limits of normal for serum
C3 are not due simply to differences in the calibration of the
assay. Difference among the C3 assays may be of clinical
significance. For example, C3 levels measured by radial immu-
nodiffusion, which has a low lower limits of normal, has
significantly less diagnostic sensitivity and specificity in active
SLE than do C3 levels measured by nephelometry, which has a
relatively high lower limits of normal [9].
In the same Centers shown in Figure 1, the range of normal
for serum C4 levels also varied widely: from 10 to 28 mg/dl
(lower limits) to 35 to 80 mg/dl (upper limits). However, in
contrast to the situation with serum C3 levels, the Centers with
the highest lower limits of normal for C4 also tended to have the
highest upper limits of normal for C4 (data not shown).
Serial assessment of complement status
Serial measurement of serum complement levels can be used
to monitor the activity of IC-mediated diseases. This issue has
been particularly well studied in patients with SLE [10—23]. At
the present time it is not clear whether measurement of C3, C4,
or both is best for monitoring SLE disease activity. However,
there is evidence that the greater the decrease in C3 or C4 levels
below normal, the more likely it is that the patient's SLE is
active [20, 22].
In SLE patients, serum C3 and C4 levels tend to change in
parallel. Figure 2 is an example of the correlation between C3
and C4 levels observed in a single patient. To determine the
variability from patient to patient in the correlation of C3 and
C4 levels, we calculated the correlation coefficient for serum C3
and C4 levels in each of 20 consecutive SLE patients with GN,
who had multiple C3 and C4 measurements by nephelometry
(mean, 32 13 SE) over a wide range of C3 and C4 levels. In
these patients the mean correlation coefficient was 0.8 0.1 SD.
Thus, in most SLE patients, measuring either serum C3 or C4
levels gives essentially equivalent information regarding the
relative change in complement levels. Nevertheless, we recom-
mend the measurement of serum C3 because it has been our
experience and the experience of others [9, 18—20, 23] that,
compared to serum C4, serum C3 levels are more likely to
change from normal to abnormal as SLE changes from quies-
cent to active. This recommendation contrasts with a previous,
widely quoted report suggesting that low C4 is a more sensitive
index of SLE activity than low C3 [18]. However, in that report
part of the reason for the higher percent of patients with
abnormally low C4 versus C3 during SLE relapse is that,
compared to C3, C4 was more likely to be abnormally low, even
during SLE remission [18]. Thus, compared to C3, C4 is less
likely to change from normal to abnormal as the patient changes
from inactive to active SLE [9, 18—20, 23]. One reason for
persistently low C4 levels in SLE patients, even during SLE
remission, is that one or more C4 null genes (genes that do not
produce C4) [24—26] are more common in SLE (50 to 80%), than
in the general population [271. Thus, some SLE patients have
low or borderline low C4 levels, even when there is no disease
activity [9, 13, 18, 20, 21]. A further reason for the decreased
diagnostic specificity of C4 in SLE is that, compared to C3, the
range of normal for C4 is large. For example, by nephelometry
assay for serum C4 there is about a 300% difference between the
lower and upper limits of normal; by contrast, for serum C3
there is only about a 60% difference between the lower and
upper limits of normal. The reason for the relatively wider range
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Fig. 2. Relationship between serum C3 and
C4 levels in a typical patient with SLE and
GN. The correlation coefficient of this
relationship is 0.93 (P < 0.001). The
complement levels in this patient were
measured by nephelometry.
of normal for C4 is that 20 to 40% of the normal population
includes individuals with one or two C4 "null" genes [271.
Thus, an SLE patient who in remission has a relatively high C4
level, can experience a considerable reduction in C4 as a result
of SLE activity, and still have the C4 level remain within the
normal range. This too will decrease the diagnostic specificity
of C4 in active SLE. Because of these difficulties in the
interpretation of serum C4 levels, we recommend measurement
of C3 levels to serially monitor complement status. Also, by
measuring just one of the complement components, the cost of
monitoring complement status is reduced by one-half.
Recent studies suggest that the measurement of the plasma
levels of the products of complement activation, such as iC3b,
C3a des Arg, C3d, C5a, or C5b-9 complex, may be useful in the
clinical evaluation of disorders of complement activation [28—
34]. For example, in patients with low levels of plasma C3, the
presence in plasma of increased levels of the stable breakdown
product, C3a des Arg is evidence that the low C3 is the result,
at least in part, of consumption of C3, not decreased synthesis
of C3. In addition, increased plasma levels of the products of
complement activation may occur before plasma levels of the
complement components become decreased. Thus, increased
plasma levels of the products of complement activation may be
a more sensitive index of complement activation than decreased
plasma levels of the complement components. Although this
approach to the evaluation of disorders of complement metab-
olism is promising, at the present time there is insufficient
experience with these methods to determine their role in the
clinical evaluation of patients with hypocomplementemia.
Causes of hypocomplementemia
Disorders in which IC formation is regarded as the primary
cause of the hypocomplementemia
Most patients who are hypocomplementemic as a result of
IC-mediated disease have decreased levels of serum or plasma
C3 and C4, indicating activation of the classical pathway.
However, there are exceptions. These are discussed below.
Evidence that classical pathway activation is the reason for low
C3 and C4 levels in a given patient can be strengthened by
measuring plasma Clq levels. The plasma concentration of this
component should also be low if the low C3 and C4 levels are
the result of classical pathway activation. Discussed below are
the disorders in which IC formation is regarded as the primary
cause of the hypocomplementemia.
1. SLE. In most studies, the majority of SLE patients with
renal manifestations have hypocomplementemia [9, 10, 14—16,
18, 21—23, 28—34]. However, extra-renal manifestations of SLE
often occur without the development of hypocomplementemia
[10, 18, 211. The hypocomplementemia (typically decreased
serum C3 and C4 levels) of SLE is thought to be the result of
activation of the classical pathway by IC [3]. However, in some
patients decreased synthesis of complement may also play a
role in causing the hypocomplementemia [351. Falling serum
complement levels can be predictive of impending SLE relapse
[10, 14, 16, 18, 21, 22]. Rising serum complement levels during
treatment of SLE can be indicative of adequate therapy [15, 16,
18, 22, 23]. The decreased C3, C4 levels of severe SLE return
to normal with effective treatment, but only slowly, For exam-
ple, four weeks after start of high-dose prednisone therapy and
cyclophosphamide therapy, serum C3 and C4 levels remain
near pre-treatment levels (mean values about 60% of the lower
limits of normal). However, by eight weeks of therapy, the
mean C3 and C4 levels have returned to normal [81. Occasion-
ally other autoimmune disorders (such as, Sjorgren's syn-
drome) can be associated with IC formation and hypocomple-
mentemia [361.
2. Idiopathic MPGN. MPGN Type 1 typically has low C3
and C4 levels which appear to be, at least in part, the result of
classical pathway activation by IC [3]. In addition, MPGN Type
1 can have NFa (C3 Nef), an antibody that stabilizes the C3
convertase C3bBb, thereby increasing C3 consumption. C3 Nef
results mainly in activation of C3 in the fluid phase. Thus,
membrane bound C3/C5 convertases do not form, and activa-
tion of the terminal pathway does not occur [3]. C3 Nef is found
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most commonly in MPGN Type 2, a disease that is not thought
to be an IC-mediated disease. Patients with MPGN type 1 can
also have NFt (nephritic factor of the terminal pathway). NFt
binds to properdin (P) stabilizing the C3 convertase C3bBbP.
This complex can activate the terminal pathway by providing a
binding site for C5b [3]. MPGN Type III has low C3 levels and
sometimes low C4 levels, apparently as a result of classical
pathway activation by IC. In addition, NFt has been identified
in patients with MPGN Type III [3].
3. Cryoglobulinemia Types I, II, and III. Decreased serum
C3 and C4 levels are seen in all three types of cryoglobulinemia
[37]. Evidently the immune aggregates that form in cryoglob-
ulinemia are able to activate the classical pathway.
4. Chronic infections causing GN/vasculitis. Bacterial in-
fections causing chronic osteomyelitis, endocarditis, infected
ventricular atrial shunts, or various types of visceral (lung,
intra-abdominal or hepatic) abscess have been associated with
formation of circulating IC, decreased serum C3 and C4 levels,
and GN [38]. Viral infections have also been associated with IC
formation and GN [38]. However, only hepatitis B virus is
known to be associated with a clinically severe form of GN/
vasculitis. Occasionally, these patients will have decreased C3
and C4 levels [39]. Parasitic/spirochetal infections that are
chronic can also be associated with IC disease and hypocom-
plementemia. Decreased C3 and C4 levels are observed [40—42].
5. Post-infectious glomerulonephritis (GN). This category
differs from chronic infections causing GN/vasculitis in that the
former condition requires the presence of a chronic active
infection to cause GN. By contrast, in typical post-infectious
GN the infection occurs acutely and then subsides. However,
days to weeks later the GN appears. Post-infectious GN is seen
following infections with certain strains of Group A beta
hemolytic streptococcus. However, streptococcus pneumoniae
and meningococcus infection have also been associated with
post-infectious GN [43—451. Although low serum C3 and C4
levels are seen in some patients early in the course of their
disease, usually it is the C3 level that is decreased throughout
the active phase of the disease [3, 38].
6. Rheumatoid vasculitis. Decreased serum C3 and C4
levels are seen during active disease, presumably the result of
high levels of circulating IC [46]. Renal involvement is unusual
in this disorder.
7. Idiopathic vasculitis. Some patients with vasculitis not
classifiable by current schema have IC-mediated disease and
hypocomplementemia. Usually both serum C3 and C4 levels
are decreased [47—49, and unpublished observations]. The
vasculitis associated with Wegener's granulomatosis, which
probably is not immune complex mediated, is not associated
with hypocomplementemia [50]. Temporal arteritis is not asso-
ciated with hypocomplementemia, but may be IC mediated
[50].
8. Repeated injection offoreign proteins. Serum sickness is
the classic example of the diseases in this category [51].
However, repeated vaccine injection can also cause decreased
C3 and C4 levels, and IC mediated GN [52].
9. Drug-induced SLE. Decreased C3 and C4 levels occur,
but are unusual in drug induced SLE [53].
10. Hypersensitivity to drugs. IC disease and hypoconiple-
mentemia have been reported in patients treated with sulfasal-
izine (decreased C3 levels) [541, potassium iodide (decreased C3
and C4 levels) [55], and chiorpropamide (decreased CH5O) [56].
11. Chemotherapy for malignant disorders. IC formation and
decreased C3 and C4 levels have been observed during chemo-
therapy for Hodgkin's disease [57] and lymphoblastic leukemia
[58].
12. Thyroid disorders. Graves' disease, radiation treatment,
or thyroiditis can result in the formation of thyroglobulin
containing IC, IC disease and decreased C3 and C4 levels [59].
13. Jejunal ileal bypass. IC-mediated arthritis, hemolysis,
and decreased C3 and C4 levels can occur in these patients [60].
The mechanism is thought to be gastrointestinal absorption of
antigens resulting in immunization and IC formation.
14. B-cell lymphoproliferative disorders. IC, formed by anti-
bodies directed at the idiotype of the monoclonal antibodies
produced by the B-cell disorder, cause increased activation of
Cl with secondary consumption of Cl inactivator, C4, and C2.
C3 levels are not decreased apparently because of defective
formation of C3 convertase [61]. Cryoglobulins are not present.
These patients can present with urticaria [61], panniculitis and
hepatitis [62, 631, and recurrent infections [64].
Causes of hypocomplementemia
Diseases/conditions in which factors other than IC formation
are regarded as the cause of the hypocomplementemia
The conditions listed below are thought to cause hypocom-
plementemia by mechanisms that do not involve the immune
system, at least not directly. In many instances it is the
alternative pathway that is activated. Thus, typically, C3 levels
are decreased but C4 levels are normal. There are, however,
numerous nonimmune causes of hypocomplementemia that
cause low C3 and C4 that may or may not be the result of
classical pathway activation. Each of these nonimmune condi-
tions causing hypocomplementemia, and the mechanism of the
hypocomplementemia is discussed below.
1. Atheromatous embolization. Spontaneous or catheter
induced atheromatous embolization can produce a systemic
disorder that can be easily confused with IC-mediated vasculi-
tis. In addition to hypocomplementemia, patients with athero-
matous embolization may show lower extremity skin rash that
resembles vasculitis, progressive renal failure, pancreatitis,
gastrointestinal bleeding, eosinophilia, and thrombocytopenia.
Decreased serum complement levels are the result of comple-
ment activation by atheromata, apparently mainly by alternate
pathway activation [65—67]. The hypocomplementemia of ath-
eroembolism is usually short lived, occurring mainly during the
period of active embolization [65].
2. Hemo/ytic-uremic syndrome/thrombolic thrombocy lope-
nic purpura (HUS/TTP). This multisystem disorder also can
easily be confused with an IC-mediated vasculitis. Decreased
C3 and sometimes decreased C4 are seen in many patients with
HUS/TTP. The decreased C3 levels may be secondary to
complement activation by toxins or microorganisms associated
with HUS, to plasminogen activation which can activate C3, or
to activation of the alternative pathway by damaged endothe-
hum [68—741. Whatever the process activating complement in
HUS/TTP, it appears to sometimes include the classical path-
way because Clq levels are also decreased in some patients
with HUS/TTP [70, 72]. Thus, serum complement levels are of
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little value in differentiating HUS/TTP from IC-mediated dis-
ease.
3. Severe sepsis. Systemic infections tend to increase serum
complement levels [75—77]. However, in severe sepsis, espe-
cially with shock, serum C3 and C4 levels can be decreased
markedly [77]. Shock without sepsis does not cause hypocom-
plementemia [77]. Severe sepsis with its fever, multisystem
involvement, hypocomplementemia and thrombocytopenia can
be confused with a severe IC-mediated vasculitis. The mecha-
nism of the hypocomplementemia of severe sepsis appears to
involve activation of the classical pathway because both C3 and
C4 levels are low, Cl-Cl inhibitor complexes form, and C3a and
C4a levels are increased [311. The mechanism by which the
classical pathway is activated appears to be proteolytic inacti-
vation of plasma Cl inhibitor [78].
4. Severe malnutrition. Marked decreases in serum Clq and
C3 have been described in severely malnourished children
[79—811. Serum C4 levels are normal [80, 81]. Of note is that the
relatively severe protein depletion that can accompany ne-
phrotic syndrome does not have any important effect on serum
C3 or C4 levels, although Clq, C2, C8, C9 and Factor B can be
low [82]. Moderately poor nutrition in adults does not have
obvious effects on serum C3 and C4 levels (unpublished obser-
vations).
5. Hepatic failure. In fulminant hepatic failure, C3 and C4
levels can decrease markedly but Clq levels are normal [83, 84].
The hypocomplementemia in fulminant hepatic failure is prob-
ably the result of decreased synthesis of C3 and C4. In addition,
in chronic active hepatitis, immune complexes can form and
complement activation is present [85]. This also can contribute
to the hypocomplementemia of liver disease.
6. Acute pancreatitis. Pancreatic proteases can convert
complement components into their active forms. This may be
the mechanism of the decreased serum C3 and C4 levels seen in
acute pancreatitis [86, 87]. Of note is that the decreased C3
levels of acute pancreatitis usually return to normal within days
of the onset of the acute pancreatitis [861. By contrast, in
patients with SLE, decreased serum C3 and C4 levels usually
require several weeks of effective treatment before they return
to normal [8].
7. Inherited abnormalities of complement pathway compo-
nents or of certain of the complement control proteins. Inher-
ited abnormalities of the complement system are rare, however,
an inherited deficiency of each of the complement components
Cl to C9, and for most of the complement control proteins have
been reported [881. Persons who are homozygous deficient for a
given complement component show virtually no CH5O activity.
ITeterozygous-deficient individuals generally show 1/2 normal
CH5O activity [881. Inherited deficiencies of complement con-
trol proteins can also result in hypocomplementemia by permit-
ting unregulated complement activation. For example, Cl in-
hibitor deficiency causes decreased levels of C2 and C4, but not
Cl and C3 [891. Factor H deficiency causes decreased levels of
C3, Factor B, and terminal pathway components [90—92].
Factor I deficiency causes decreased levels of C3, Factor B,
and the terminal pathway components, and a mild decrease in
C4 levels [93, 941. Deficiencies of C4 binding protein [951 and
properdin [961 are not associated with hypocomplementemia.
Inherited structural abnormality of complement factors can also
result in hypocomplementemia. An example is an inherited
abnormal C3 that forms a C3 convertase which is resistant to
degradation by Factors H and I [97].
IC-mediated diseases are common in patients with comple-
ment pathway abnormalities that result in deficient C3 activa-
tion [98, 99]. This tendency to IC-mediated disease may be the
result of increased precipitability of IC that form in the plasma
of patients who are complement deficient, decreased capacity
of the plasma of patients with complement deficiencies to
solubilize already deposited IC, or impaired function of the
erythrocyte IC-clearing mechanism in the hypocomplement-
emic patient [98, 99]. Patients with inherited abnormalities that
affect terminal complement pathway activation usually have an
increased incidence of infection, particularly Neisserial infec-
tiOns [98, 99]. Infections are also more common in patients with
abnormalities of classical and alternative pathway activation
[98, 99]. Thus, patients with inherited deficiencies of comple-
ment components, or their control proteins, can have decreased
C3 and C4 levels because of the effects of infection and/or IC
formation.
8. Thermal burns. Marked reductions in serum C3 and C4
have been noted in patients with severe burns involving 25% to
90% of body surface area [100].
9. Acute myocardial infarction. Mild to moderate acute
reductions in C3 and C4 have been reported in some but not all
patients with acute myocardial infarction [101, 1021. The mech-
anism of the hypocomplementemia is unknown.
10. Intravascular infusion of agents that can activate com-
plement. Intravascular infusion of radiographic contrast agents
can cause mild complement activation and transient reductions
in serum C3 levels. Alternative pathway complement activation
has been demonstrated with conventional angiographic agents
as well as with the newer hypoosmolar, nonionic radiocontrast
agents [103—108]. Complement activation may contribute to
acute adverse reactions associated with infusion of radiocon-
trast agents [108]. Inulin is a complex polysaccharide that also
can activate the alternative complement pathway. Inulin levels
greater than 26 mgldl result in modest acute reductions in C3
levels [109]. Heparin-protamine complexes have been shown to
activate the classical pathway in vitro [1101 and in vivo, in
animals [lii]. However, very large doses of heparin and
protamine (beyond the therapeutic range in humans) are needed
to reduce serum complement levels.
11. Hemodialysis. Cuprophane dialysis membranes cause a
modest transient reduction in serum C3 levels but usually not
outside the range of normal [112, 113]. Cellulose acetate,
polycellulose acetate, and polymethylmethacrylate membranes
do not cause reductions in serum C3 or C4 levels with long-term
use [113]. The mechanism of the hypocomplementemia is
alternative pathway activation by the dialysis membrane [114].
12. Cardiopulmonary bypass. Mild transient reductions in
C3 and C4 occur during cardiopulmonary bypass. The mecha-
nism is thought to be complement activation by the nylon mesh
bubble oxygenators as well as by vigorous oxygenation of
whole blood [115—1 18].
13. Hemolytic crisis in malaria. The decrease in serum C3
and C4 levels in this disorder seems to be multifactorial.
Alternative pathway activation by the malaria organisms, de-
creased synthesis of C3 and C4 by the liver because of hepatic
infection, and IC formation during acute hemolysis can account
for the hypocomplementemia seen in malaria [1191.
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Table 2. Common nonimmunologic diseases that can mimic an IC-
mediated vasduhitis because they cause multisystem disorders and
hypocomplementemia
Complement
Disease levels Comment
1) Atheroembolism C3, C4 The hypocomplementemia is
transient, occurring only
during active embolization'
2) Severe sepsis . C3, C4 The development of shock
increases likelihood of
sepsis causing
hypocomplementemia
3) HUS/TTP C3, C4 Hypocomplementemia occurs
in about 1/2 of cases
4) Acute pancreatitis C3, C4 The hypocomplementemia
clears in a few daysa
a By contrast, the hypocomplementemia of active SLE usually re-
quires weeks to return to normal, with successful therapy.
14. Systemic viral infection. A large kindred with recurrent
Herpes simplex infection has been reported in which serum C4
levels were normal but serum C3 levels and terminal pathway
components were decreased [1201. The mechanism of the
hypocomplementemia is thought to be alternative pathway
activation by virally infected cells.
15. Porphyria. Exposure of patients with erythropoietic pro-
toporphyria to sunlight results in decreased serum C3 levels, as
a result of activation of the alternative pathway [1211.
Table 2 shows the key nonimmunologic disorders that can
closely mimic an IC-mediated systemic vasculitis because they
cause a multi-system disorder with hypocomplementemia. Ta-
ble 3 summarizes the non-immunologic conditions that can
cause hypocomplementemia and, should they complicate the
course of a patient with inactive IC-mediated disease, could
spuriously suggest the presence of active IC-mediated disease.
Thus, these tables summarize the key differential diagnostic
problems in the evaluation of the hypocomplementemic patient.
Immune complex-mediated renal diseases that are rarely or
never associated with hypocomplementemia
Hypocomplementemia is particularly common in IC-medi-
ated diseases that cause GN. The reason for this association
may be the magnitude of IC formation that is needed before
there is sufficient deposition of IC in glomeruli to induce GN.
Nevertheless, in some forms of IC-mediated renal disease,
hypocomplementemia is conspicuously absent. The reasons
why hypocomplementemia is absent in some forms of IC-
mediated GN is not clear. However, it may relate to the fact
that, in some IC-mediated renal diseases (such as, idiopathic
membranous nephropathy), the IC are the result of in situ IC
formation and are present only in the kidney. Thus, the IC may
have formed only outside the circulation and, the total mass of
IC formed may be relatively small. Therefore relatively little
complement activation occurs. In any event, it is important to
recognize that there are certain types of IC-mediated renal
diseases in which hypocomplementemia is not observed. For
completeness sake this list of diseases is provided below.
Table 3. Common non-immunologic conditions that can cause
hypocomplementemia and, should they be present in a patient with
inactive IC-mediated disease, could spuriously suggest activity of the
IC-mediated disease
Complement
Condition levels Comment
1) The conditions See Table 2 See Table 2
listed in Table 2
2) Severe C3, NI C4 Clq is also low
malnutritiona
3) Severe liver C3, . C4 Clq levels are normal
disease
4) Inherited C4 NI C3, C4 20—40% of normals have
deficiency 1 or 2 C4 null genes.
SLE patients have a
higher incidence of
this genetic defect
Abbreviations are: NI, normal; , decreased.
a The protein depletion of uncomplicated nephrotic syndrome does
not cause low C3 or C4 levels.
I. Membranous nephropathy: Idiopathic[122], drug-induced
[123—125] or cancer associated [126—129]. If hypocomplement-
emia is observed in a patient with membranous nephropathy,
SLE or another systemic IC-mediated disease should be sus-
pected [122].
2. The GN/vasculitis of Henoch-SchOnlein purpura (HSP).
Despite severe systemic vasculitis and evidence of complement
deposition in the IgA deposits, hypocomplementemia is only
occasionally observed in this disease [4, 130, unpublished
observationsi. The reason why even severe systemic vasculitis
can occur with IgA-IC without causing hypocomplementemia is
not clear. However, it may relate to the decreased capacity of
IgA-IC to activate complement and/or to greater rates of tissue
deposition of IgA-IC, compared to IC composed of other Ig
[131—132]. Thus, compared to other IC mediated diseases, HSP
may be able to cause a systemic vasculitis at lower rates of IC
formation, rates that do not cause hypocomplementemia.
3. IgA nephropathy (Berger's disease). This disorder, like
HSP, is primarily associated with IgA-IC deposition. Despite an
increased frequency of C4 null genes [133], hypocomplement-
emia is absent [4, 38], perhaps for the reasons discussed in
connection with HSP.
4. Goodpasture's disease. Complement-fixing antibodies are
deposited on antigens in lung and kidney; however, hypocom-
plementemia is not seen [4, 38].
5. Immunotactoid glomerulopathy. This recently described
disorder derives its name from immunoglobulin deposits that
form tactoids in glomeruli. C3 and Clq are present in glomer-
ular deposits, but usually the patients are not hypocomplement-
emic [134, 135].
6. CIq glomerulopathy. This recently described glomerular
disorder is not associated with SLE, but contains abundant
glomerular deposits of Cl q and immunoglobulins, but hypo-
complementemia is absent [136].
Conditions/disorders that can raise serum complement levels
Certain conditions can raise serum complement levels and,
therefore, could offset the effect of IC diseases to lower serum
complement levels. Of particular relevance in this regard are
pregnancy, systemic infections, and noninfectious chronic in-
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flammatory states such as rheumatoid arthritis. If these condi-
tions coexist with an active IC-mediated disorder, it is possible
that hypocomplementemia might not develop, even though the
IC-mediated disease is active. The interaction between a con-
dition that can raise complement levels and a condition that can
lower serum complement levels has been particularly well
described in SLE patients who became pregnant [137, 1381. In
normal pregnancy, serum complement levels often increase to
above normal values. Thus, a "normal" complement level in a
pregnant SLE patient could indicate activity of her SLE.
Summary
Hypocomplementemia is an important marker for the pres-
ence of IC-mediated disease and can be used to assess disease
activity. However, in interpreting the clinical significance of
hypocomplementemia, the following must be kept in mind: 1)
There are numerous non-immunologic conditions that also can
cause hypocomplementemia. Furthermore, some of these con-
ditions can cause a multisystem disease that, along with the
hypocomplementemia, can closely resemble an IC-mediated
systemic vasculitis. Furthermore, these nonimmunologic con-
ditions that lower serum complement levels can complicate the
course of patients with inactive IC-mediated disease, spuriously
indicating that the disease is active. The most relevant of these
differential diagnostic problems are listed in Table 2. 2) There
are a few conditions (for example, pregnancy) that can raise
serum complement levels, thereby possibly obscuring the pres-
ence of a disorder (such as, active SLE) that is lowering
complement levels. 3) There are some conditions that might be
expected to lower serum complement levels, because of their
effect on protein metabolism, but do not. Nephrotic syndrome,
and moderately poor nutrition are examples. All of these factors
should be considered when interpreting results of serum corn-
plement levels in a given patient.
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